Brightcove Named Leader in The Aragon Research Globe™ for Enterprise Video, 2023 Report
8.5.2023 16:00:00 EEST | Business Wire | Press release
Brightcove (Nasdaq: BCOV), the world’s most trusted streaming technology company, was named a “Leader” by Aragon Research, Inc. in “The Aragon Research Globe™ for Enterprise Video, 2023” report for a second consecutive year.
“We’re honored to be identified as a Leader for enterprise video in The Aragon Research Globe for Enterprise Video, 2023 report. The report focuses on exciting solutions and strategies for enterprises to grow business with streaming video, which aligns with Brightcove’s offerings,” said Scott Levine, SVP and Head of Product at Brightcove. “Some ways we’re innovating and meeting customer demands include advancing video-first internal communications experiences via our Communications Studio offering and broadening e-commerce integrations to allow businesses to engage buyers with interactive video.”
Brightcove’s platform focuses on scalability, stability and flexibility for its video marketing platform, video analytics, social video management, and live broadcast and OTT capabilities. The company has a wide breadth of integrations with interactivity and e-commerce solutions, end-to-end analytics platforms with actionable data, digital asset and content management systems, and meeting automation platforms, alongside the platform’s premium video experiences across all endpoints (web, mobile, and smart TVs). “The full and connected suite of Brightcove’s products, solutions and services helps organizations implement a video-first strategy to drive revenue and engage customers, employees and audiences at a deeper level,” added Levine.
Aragon Research defines the Leader position as companies that “have comprehensive strategies that align with industry direction and market demand and effectively perform against those strategies.” Brightcove emerged in the enterprise video market at a time when employees and customers continue to consider video the most engaging form of communication and the catalyst for better experiences that drive business outcomes.
“In our research for the Enterprise Video Globe Report, we looked into product performance, strategy, and vision of each company,” said Jim Lundy, CEO of Aragon Research. “Brightcove has made significant progress on its strategic priorities with innovation investments that have broadened its solution and services offerings while showcasing that their scale and reliability is a differentiator.”
The ninth annual “The Aragon Research Globe™ for Enterprise Video, 2023” evaluated 14 enterprise video vendors deemed to be making a difference in better customer and employee experiences.
For more information and to read The Aragon Research Globe™ for Enterprise Video, 2023 report, visit Brightcove.com.
Aragon Research does not endorse vendors, or their products or services that are referenced in its research publications, and does not advise users to select those vendors that are rated the highest. Aragon Research publications consist of the opinions of Aragon Research and Advisory Services organization and should not be construed as statements of fact. Aragon Research provides its research publications and the information contained in them "AS IS," without warranty of any kind.
About Aragon Research
Aragon Research is an independent research and advisory firm that provides business and IT executives with the actionable insights they need to navigate technology's ever-evolving impact on business. Headquartered in Morgan Hill, CA, Aragon Research works with executives at every major level of the business and across industries to give them the tools they need to make more informed technology and strategy decisions. Aragon delivers high-impact advisory, research, and consulting services, and has a proven team of veteran analysts. For more information, visit www.aragonresearch.com.
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow on LinkedIn, Twitter, Facebook and Instagram. Visit www.brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230508005060/en/
Contact information
Media
Joseph J. Nuñez, Director of Global Communications and Public Relations
jnunez@brightcove.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom